Cadrenal Therapeutics develops biopharmaceutical therapies for life-threatening immune and thrombotic conditions. News about Cadrenal Therapeutics centers on CAD-1005, its investigational selective 12-lipoxygenase inhibitor for heparin-induced thrombocytopenia, including clinical-study results, FDA communications, pivotal-trial design guidance, and research involving the broader 12-LOX inhibitor platform.
Company updates also cover pipeline assets such as tecarfarin, an oral vitamin K antagonist for chronic anticoagulation settings, and frunexian, a parenteral Factor XIa inhibitor for acute hospital use. Recurring financial news includes quarterly results, cash resources, equity financings, and strategic alternatives tied to the company’s clinical development plans.
Cadrenal Therapeutics (Nasdaq: CVKD) announced the closing of its initial public offering, successfully selling 1,400,000 shares at $5.00 each, raising $7 million before expenses. The offering commenced trading on the Nasdaq Capital Market on January 20, 2023. The firm has granted underwriters a 45-day option to purchase an additional 210,000 shares. Cadrenal is focused on developing tecarfarin, a novel therapy for preventing blood clots in patients with end-stage renal disease and atrial fibrillation, holding orphan drug and Fast Track designations. The press release also contains forward-looking statements regarding future expectations.
Cadrenal Therapeutics (Nasdaq: CVKD) announced that its drug, tecarfarin, has received Fast Track designation from the FDA for preventing blood clots in patients with end-stage renal disease (ESRD) and atrial fibrillation (AFib). This designation aims to expedite the drug's development and review due to an unmet medical need. Tecarfarin, which targets a different pathway than existing anticoagulants, has previously been granted Orphan Drug Designation. The company plans to collaborate closely with the FDA to advance clinical trials for this therapy, which has undergone evaluation in over 1,000 individuals, aiming to optimize stroke prevention in this underserved patient group.